Who are Tolterodine 6's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tolterodine Tartrate ER, Detrol LA, Atropine 1%, Atropine Sulfate 0.04% Eye Drop, Atropine sulfate eye drops 0.01%, Atropine Sulfate 02.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tolterodine-6.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Tolterodine 6 — Competitive Intelligence Brief

Tolterodine 6 (Tolterodine 6) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Muscarinic receptor antagonist. Area: Urology.

marketed Muscarinic receptor antagonist M2 and M3 muscarinic receptors Urology Small molecule Live · refreshed every 30 min

Target snapshot

Tolterodine 6 (Tolterodine 6) — KYU-SUNG LEE. Tolterodine is a muscarinic receptor antagonist that blocks acetylcholine signaling in the bladder to reduce involuntary contractions and urinary urgency.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Tolterodine 6 TARGET	Tolterodine 6	KYU-SUNG LEE	marketed	Muscarinic receptor antagonist	M2 and M3 muscarinic receptors
Tolterodine Tartrate ER	Tolterodine Tartrate ER	University of California, San Francisco	marketed	Muscarinic receptor antagonist	M2 and M3 muscarinic receptors
Detrol LA	Detrol LA	Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	marketed	Muscarinic receptor antagonist	M2 and M3 muscarinic acetylcholine receptors
Atropine 1%	Atropine 1%	Massachusetts Eye and Ear Infirmary	marketed	Anticholinergic agent / Muscarinic receptor antagonist	Muscarinic acetylcholine receptors (M1-M5, primarily M3 in ocular tissue)
Atropine Sulfate 0.04% Eye Drop	Atropine Sulfate 0.04% Eye Drop	Shanghai Eye Disease Prevention and Treatment Center	marketed	Anticholinergic agent / Muscarinic receptor antagonist	Muscarinic acetylcholine receptors (M1, M3, M5)
Atropine sulfate eye drops 0.01%	Atropine sulfate eye drops 0.01%	Oupushifang Pharmaceutical Technology Co., Ltd.	phase 3	Muscarinic receptor antagonist	Muscarinic acetylcholine receptors (M1, M3)
Atropine Sulfate 02	Atropine Sulfate 02	LitePharmTech Co., Ltd.	phase 3	Anticholinergic agent / Muscarinic receptor antagonist	Muscarinic acetylcholine receptors (M1-M5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Muscarinic receptor antagonist class)

KYU-SUNG LEE · 1 drug in this class
Oupushifang Pharmaceutical Technology Co., Ltd. · 1 drug in this class
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · 1 drug in this class
R-Pharm · 1 drug in this class
University of California, San Francisco · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tolterodine 6 — Competitive Intelligence Brief. https://druglandscape.com/ci/tolterodine-6. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab